Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway
Type-2 diabetics have an increased risk of cardiomyopathy, and heart failure is a major cause of death among these patients. Growing evidence indicates that proinflammatory cytokines may induce the development of insulin resistance, and that anti-inflammatory medications may reverse this process. We...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
6 May 2016
|
| In: |
Cardiovascular diabetology
Year: 2016, Volume: 15, Issue: 1 |
| ISSN: | 1475-2840 |
| DOI: | 10.1186/s12933-016-0383-8 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s12933-016-0383-8 |
| Author Notes: | Sevil Korkmaz-Icöz, Samer Al Said, Tamás Radovits, Shiliang Li, Maik Brune, Péter Hegedűs, Ayhan Atmanli, Mihály Ruppert, Paige Brlecic, Lorenz Heyne Lehmann, Bernd Lahrmann, Niels Grabe, Yutaka Yoshikawa, Hiroyuki Yasui, Patrick Most, Matthias Karck and Gábor Szabó |
| Summary: | Type-2 diabetics have an increased risk of cardiomyopathy, and heart failure is a major cause of death among these patients. Growing evidence indicates that proinflammatory cytokines may induce the development of insulin resistance, and that anti-inflammatory medications may reverse this process. We investigated the effects of the oral administration of zinc and acetylsalicylic acid, in the form of bis(aspirinato)zinc(II)-complex Zn(ASA)2, on different aspects of cardiac damage in Zucker diabetic fatty (ZDF) rats, an experimental model of type-2 diabetic cardiomyopathy. |
|---|---|
| Item Description: | Gesehen am 12.09.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1475-2840 |
| DOI: | 10.1186/s12933-016-0383-8 |